Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma

Cancer

Volumn 104, Issue 4, 2005, Pages 730-739

  Casson, Alan G ^a,b   Zheng, Zuoyu ^a   Evans, Susan C ^a   Geldenhuys, Laurette ^a   Van Zanten, Sander Veldhuyzen ^a   Veugelers, Paul J ^a   Porter, Geoffrey A ^a   Guernsey, Duane L ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Adenocarcinoma; Barrett epithelium; CCND1; Cyclin D1; Esophagus; Gastroesophageal reflux disease; Polymorphism

Indexed keywords

CYCLIN D1; GENOMIC DNA;

ADULT; ARTICLE; BARRETT ESOPHAGUS; CANCER RISK; CASE CONTROL STUDY; CELL CYCLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA EXTRACTION; DNA POLYMORPHISM; ESOPHAGEAL ADENOCARCINOMA; EXON; FEMALE; GASTROESOPHAGEAL REFLUX; GENE AMPLIFICATION; GENE FREQUENCY; GENE OVEREXPRESSION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; POLYACRYLAMIDE GEL ELECTROPHORESIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN FUNCTION; RISK FACTOR; WILD TYPE;

ADENOCARCINOMA; BARRETT ESOPHAGUS; CYCLIN D1; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PRECANCEROUS CONDITIONS; RISK FACTORS;

EID: 23444432689     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21229     Document Type: Article

References (54)

1. DeMeester SR, DeMeester TR. Columnar mucosa and intestinal metaplasia of the esophagus. Fifty years of controversy. Ann Surg. 2000;231:303-321.
2. Specher SJ. Clinical practice. Barrett's esophagus. N Engl J Med. 2002;346:836-842.
3. Jankowski JA, Wright NA, Meltzer SJ, et al. Molecular evolution of the metaplasia-dysplasia-adenocarcinoma sequence in the esophagus. Am J Pathol. 1999;154:965-973.
4. Shaheen N, Ransohoff DF. Gastroesophageal reflux, Barrett's esophagus and esophageal cancer. JAMA. 2002;287: 1972-1981.
5. Blot WJ, McLaughlin JK. The changing epidemiology of esophageal cancer. Semin Oncol. 1999;26:2-8.
6. Gammon MD, Schoenberg JB, Ahsan H, et al. Tobacco, alcohol and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia. J Natl Cancer Inst. 1997; 89:1277-1284.
7. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999;340:825-831.
8. Mayne ST, Risch HA, Dubrow R, et al. Nutrient intake and risk of subtypes of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev. 2001;10:1055-1062.
9. Vaughan TL, Kristal AR, Blount PL, et al. Nonsteroidal antiinflammatory drug use, body mass index and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 2002;11:745-752.
10. Reid BJ, Blount PL, Rabinovitch PS. Biomarkers in Barrett's esophagus. Gastrointest Endosc Clin N Am. 2003;13:369-397.
11. Casson AG. Role of molecular biology in the follow-up of patients who have Barrett's esophagus. Chest Surg Clin N Am. 2002;12:93-111.
12. Pagano M, Thedoras AM, Tam SW, Draetta GF. Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. Genes Dev. 1994;8:1627-1639.
13. Tam SW, Thedorad AM, Shay JW, Draetta GF, Pagano M. Differential expression and regulation of cyclin D1 protein in normal and tumor human cells: association with Cdk4 is required for cyclin D1 function in G1 progression. Oncogene. 1994;9:2663-2674.
14. Diehl JA, Sherr CJ. A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. Mol Cell Biol. 1997;17:7362-7374.
15. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway. Genes Dev. 1997;11: 957-972.
16. Lan Z, Sever-Chroneos Z, Strobeck MW, et al. DNA damage invokes mismatch repair-dependent cyclin D1 attenuation and retinoblastoma signaling pathways to inhibit CDK2. J Biol Chem. 2002;277:8372-8381.
17. Lutzen A, Bisgaard HC, Rasmussen LJ. Cyclin D1 expression and cell cycle response in DNA mismatch repair-deficient cells upon methylation and UV-C damage. Exp Cell Res. 2004;292:123-134.
18. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer. 2001;1:222-231.
19. Murray AW. Recycling the cell cycle: cyclins revisited. Cell. 2004;116:221-234.
20. Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699-2711.
21. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. Minireview: cyclin D1: normal and abnormal functions. Endocrinology. 2004;145:5439-5447.
22. Jiang W, Zhang YJ, Kahn SM, et al. Altered expression of cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc Natl Acad Sci USA. 1993;90:9026-9030.
23. Arber N, Lightdale C, Rotterdam H, et al. Increased expression of the cyclin D1 gene in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev. 1996;5:457-459.
24. Bani-Hani K, Martin IG, Hardie LJ, et al. Prospective study of cyclin D1 overexpression in Barrett's esophagus: association with increased risk of adenocarcinoma. J Natl Cancer Inst. 2000;92:1316-1321.
25. Miller CT, Moy JR, Lin L, et al. Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia. Clin Cancer Res. 2003;9:4819-4825.
26. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WDJ, Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene. 1995;11:1005-1011.
27. McKay JA, Douglas JJ, Ross VG, Curran S, Murray GI, McLeod HL. Cyclin D1 protein expression and gene polymorphism in colorectal cancer. Int J Cancer. 2000;88:77-81.
28. Zheng Y, Shen H, Sturgis EM, et al. Cyclin D1 polymorphism and risk for squamous cell carcinoma of the head and neck: a case-control study. Carcinogenesis. 2001;22:1195-1199.
29. Wang L, Habuchi T, Takahashi T, et al. Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer. Carcinogenesis. 2002;23:257-264.
30. Le Marchand L, Seifreid A, Lum-Jones A, Donlon T, Wilkens LR. Association of the cyclin D1 polymorphism with advanced colorectal cancer. JAMA. 2003;290:2843-2848.
31. Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis. 2003;24:1499-1503.
32. Yu J, Habuchi T, Tsuchiya N, et al. Association of the cyclin D1 gene G870A polymorphism with susceptibility to sporadic renal cell carcinoma. J Urol. 2004;172:2410-2413.
33. Nishimoto IN, Pinheiro NA, Rogatto SR, et al. Cyclin D1 gene polymorphism as a risk factor for squamous cell carcinoma of the upper aerodigestive tract in non-alcoholics. Oral Oncol. 2004;40:604-610.
34. Monteiro E, Varzim G, Pires AM, Teixeira M, Lopes C. Cyclin D1 A870G polymorphism and amplification in laryngeal squamous cell carcinoma: implications of tumor localization and tobacco exposure. Cancer Detect Prev. 2004;28:237-243.
35. Izzo JG, Papadimitrakopoulou V, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression to upper aerodigestive tract cancer. J Natl Cancer Inst. 2003;95:198-205.
36. Lewis RC, Bostick RM, Xie D, et al. Polymorphism of the cyclin D1 gene, CCND1, and risk for incidental sporadic colorectal adenomas. Cancer Res. 2003;63:8549-8553.
37. Yu C, Lu W, Tan W, et al. Lack of association between CCND1 G870A polymorphism and risk of esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev. 2003;12:176.
38. Zhang J, Li Y, Wang R, et al. Association of cyclin D1 (G870A) polymorphism with susceptibility to esophageal and gastric cardia carcinoma in a northern Chinese population. Int J Cancer. 2003;105:281-284.
39. Casson AG, Evans SE, Gillis A, et al. Clinical implications of p53 tumor suppressor gene mutation and protein expression in esophageal adenocarcinoma: results of a 10-year prospective study. J Thorac Cardiovasc Surg. 2003;27:139-146.
40. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem. 2003;278: 30339-30347.
41. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res. 2003;63:7056-7061.
42. Wang LD, Shi ST, Zhou Q, et al. Changes in p53 and cyclin D1 protein levels and cell proliferation in different stages of human esophageal and gastric-cardia carcinogenesis. Int J Cancer. 1994;59:514-519.
43. Papadimitrakopoulou VA, Izzo J, Mao L, et al. Cyclin D1 and p16 alterations in advanced premalignant lesions of the upper aerodigestive tract: role in response to chemoprevention and cancer development. Clin Cancer Res. 2001;7:3127-3134.
44. De Falco M, Fedele V, De Luca L, et al. Evaluation of cyclin D1 expression and its subcellular distribution in mouse tissues. J Anat. 2004;205:405-412.
45. Nagasawa S, Onda M, Sasajima K, et al. Cyclin D1 overexpression as a prognostic factor in patients with esophageal carcinoma. J Surg Oncol. 2001;78:208-214.
46. Prognostic significance of CyclinD1 and E-Cadherin in patients with esophageal squamous cell carcinoma: multiinstitutional retrospective analysis. Research Committee on Malignancy of Esophageal Cancer, Japanese Society for Esophageal Diseases. J Am Coll Surg. 2001;192:708-718.
47. Natsugoe S, Nakashima S, Matsumoto M, et al. Biologic and imaging diagnosis of lymph node metastasis in esophageal carcinoma. J Surg Oncol. 2002;81:25-32.
48. Arber N, Gammon MD, Hibshoosh H, et al. Overexpression of cyclin D1 occurs in both squamous carcinomas and adenocarcinomas of the esophagus and in adenocarcinomas of the stomach. Hum Pathol 1992;30:1087-1092.
49. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst. 2001;93:1054-1061.
50. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry to identify low-and high-risk patient subsets. Am J Gastroenterol. 2000;95:1669-1676.
51. Rabinovitch PS, Longton G, Blount PL, Levine DS, Reid BJ. Predictors of progression to Barrett's esophagus III: baseline flow cytometric variables. Am J Gastroenterol. 2001;96:3071-3083.
52. Reid BJ, Prevo LJ, Galipeau PC, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol. 2001;96:2839-2848.
53. Garte S, Gaspari L, Alexandrie AK, et al. Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev. 2001;10:1239-1248.
54. Miller DP, Liu, G, De Vito I, et al. Combinations of the variant genotypes of GSTP1, GST M1, and p53 are associated with an increased lung cancer risk. Cancer Res. 2002;62: 2819-2823.